Plain-English translation of NCT05938972 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is tracking how biologic medications work in patients with severe nasal polyps (growths in the nose) and/or severe asthma. Researchers want to understand which patients benefit most from this treatment and why, by measuring symptom improvement and studying samples from your nose, blood, and tissues over two years.
Many patients with severe nasal polyps or asthma don't respond equally well to the same biologic medications. This study aims to identify biomarkers—biological clues in your body—that can predict who will benefit most from this treatment, so doctors can prescribe the right therapy for each patient.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital's nose and lung clinics regularly over 24 months while taking your prescribed biologic medication. At these visits, doctors would examine your nasal polyps, assess your symptoms using questionnaires and simple tests, and collect samples (blood, nasal secretions, and small tissue samples) to study how your immune system responds to treatment. The research team tracks whether your symptoms improve and identifies which biological markers in your body predict your response to the medication.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Belgium
Sponsor
University Hospital, Ghent
Enrollment target
~180 participants
Started
March 2022
Primary completion
December 2030
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in April 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Manon Blauwblomme, Masters
University Hospital, Ghent
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.